INC Research Releases New White Paper on Transformational Change in Global Drug Development
(Thomson Reuters ONE) -
Paper Provides Insights into How CROs Are Employing Science
and Technology Innovations to Transform Clinical Development Programs
Raleigh, NC, Feb. 7, 2012 - INC Research, LLC, a therapeutically focused
clinical research organization (CRO) with a trusted process for delivering
reliable results, today announced it has released a new white paper titled, "The
Innovation Imperative: How CROs Are Driving The Transformation of Clinical
Research." INC Research's paper takes a critical look at the most significant
innovations in science and technology and how CROs are implementing these
advancements to transform the overall clinical development process.
"The drug development industry is experiencing a new wave of R&D innovation,
primarily as a response to financial pressures," said INC Research CEO James
Ogle. "CROs are in a position to not only take costs out of the clinical
development process, but also to spawn new approaches and techniques to the
process itself. As a result, modern alliance partnership models will help bring
better and safer drugs to market more efficiently."
The recent shift in the biopharmaceutical company-CRO relationship from project-
specific outsourcing to strategic alliances has created an environment in which
biopharms are considering CROs innovation partners. Based on furthering
portfolio objectives, these multi-year alliances are based on higher levels of
engagement with the CRO and leverage years of perspective, expertise and
tactical approaches. INC Research's white paper highlights how partnership
models are evolving and explores the ways CROs are transforming the practice of
clinical trials by applying digital and scientific innovations, including better
study designs for more efficient endpoints and next-generation data management
and patient recruitment strategies to accelerate new drug development.
INC Research is at the forefront of innovating all stages of the clinical trial
process, from initial first-in-human clinical trial designs to Phase IV trials.
Working with INC Research, customers access innovations that bring new life to
existing clinical development programs and accelerate new ones, helping them to
achieve their biggest R&D ambitions.
To download a copy of "The Innovation Imperative: How CROs Are Driving The
Transformation of Clinical Research," visitwww.incresearch.com/transform. For
more information on INC Research's clinical development capabilities and
comprehensive clinical and consulting services, click here.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conductingglobal clinical development programs
of the highest integrity. Pharmaceutical and biotechnology companies look to INC
Research for a complete range of customized Phase I through Phase IV programs in
all therapeutic areas and innovative pediatric and women's health trials. The
Company's Trusted Process(®) methodology and therapeutic foresight lead
customers to more confident, better-informed drug and device development
decisions. INC Research is headquartered in Raleigh, NC. For more information,
please visit www.incresearch.com or follow us at (at)inc_research.
CONTACT:
Lori Dorer, Media, (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1583389]
Unternehmensinformation / Kurzprofil:
Datum: 07.02.2012 - 16:49 Uhr
Sprache: Deutsch
News-ID 112062
Anzahl Zeichen: 4185
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Releases New White Paper on Transformational Change in Global Drug Development"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
